Original Article

You have full text access to this OnlineOpen article

Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome†

  1. Celeste Bello MD1,*,
  2. Daohai Yu PhD2,
  3. Rami S. Komrokji MD1,
  4. Weiwei Zhu MS2,
  5. Gene A. Wetzstein PharmD1,
  6. Alan F. List MD1,
  7. Jeffrey E. Lancet MD1

Article first published online: 8 NOV 2010

DOI: 10.1002/cncr.25598

Issue

Cancer

Cancer

Volume 117, Issue 7, pages 1463–1469, 1 April 2011

Additional Information

How to Cite

Bello, C., Yu, D., Komrokji, R. S., Zhu, W., Wetzstein, G. A., List, A. F. and Lancet, J. E. (2011), Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer, 117: 1463–1469. doi: 10.1002/cncr.25598

Author Information

  1. 1

    Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

  2. 2

    Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

*Moffitt Cancer Center, 12901 Magnolia Dr., FOB3, Tampa, FL 33612

  1. †

    These results were presented as a poster abstract at the American Society of Clinical Oncology Annual Meeting, Orlando, Florida, May 20, 2009.

Publication History

  1. Issue published online: 18 MAR 2011
  2. Article first published online: 8 NOV 2010
  3. Manuscript Accepted: 20 JUL 2010
  4. Manuscript Revised: 8 JUL 2010
  5. Manuscript Received: 11 JAN 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (202K)

REFERENCES

  • 1
    Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999; 341: 1051-1062.
  • 2
    Surveillance, Epidemiology, and End Results Program. Acute Myeloid Leukemia Incidence for 2000-2004. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2007. Available at: www.seer.cancer.gov Accessed November 2009.
  • 3
    Litzow MR. The therapy of relapsed acute leukaemia in adults. Blood Rev. 2004; 18: 39-63.
  • 4
    Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006; 107: 3481-3485.
  • 5
    Kantarjian H, O Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006; 106: 1090-1098.
    Direct Link:
  • 6
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood. 1998; 92: 2322-2333.
  • 7
    Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001; 98: 1312-1320.
  • 8
    Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000; 96: 4075-4083.
  • 9
    Lancet JE, Willman CL, Bennett JM. Acute myelogenous leukemia and aging: clinical interactions. Hematol Oncol Clin North Am. 2000; 14: 251-267.
  • 10
    Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989; 7: 1268-1274.
  • 11
    Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995; 86: 457-462.
  • 12
    Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007; 109: 265-273.
    Direct Link:
  • 13
    Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20: 2429-2440.
  • 14
    List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355: 1456-1465.
  • 15
    Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981; 58: 1203-1212.
  • 16
    Swerdlow SH, Campo E, Harris NL, et al. World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008.
  • 17
    Byrd JJC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336.
  • 18
    Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96: 3671-3674.
  • 19
    Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood. 2009; 113: 659-667.
  • 20
    List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 1996; 10: 937-942.
  • 21
    Desiderato L, Davey MW, Piper AA. Demethylation of the human MDR1 5-region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline. Somat Cell Mol Genet. 1997; 23: 391-400.
  • 22
    Kusaba H, Nakayama M, Harada T, et al. Maintenance of hypomethylation status and preferential expression of exogenous human MDR1/PGY1 gene in mouse L cells by YAC mediated transfer. Somat Cell Mol Genet. 1997; 23: 259-274.
  • 23
    Kantharidis P, El-Osta A, deSilva M, et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res. 1997; 3: 2025-2032.
View Full Article (HTML) Get PDF (202K)